GlassScriptPhysician profile
Shellie Renee Norman
NPI 1841609971
$6,338.71
in general payments reported to CMS, 2019-2025
19 companies · $1,079 in 2025
The $1,079 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,289 · 2022: $1,057 · 2023: $1,140 · 2024: $1,774 · 2025: $1,079.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,753 · Education: $240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,752.94 |
| Education | $240.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,580.92 | 2021-2025 | |
| Amgen INC. | $1,039.12 | 2021-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $1,014.17 | 2021-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $526.01 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $458.22 | 2021-2024 | Winlevi, Ilumya |
| Lilly USA, LLC | $436.18 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $325.28 | 2024 | |
| Janssen Biotech, INC. | $160.66 | 2021-2025 | Simponi, Simponi Aria, Tremfya |
| Galderma Laboratories, L.P. | $153.70 | 2021-2025 | Dysport, Nemluvio |
| Ucb, INC. | $111.45 | 2024-2025 | Bimzelx |
| Genzyme Corporation | $99.21 | 2021-2023 | |
| Pfizer INC. | $98.62 | 2022 | |
| Sanofi-Aventis U.S. LLC | $92.00 | 2024 | |
| Leo Pharma INC. | $65.45 | 2021-2024 | Adbry |
| Allergan, INC. | $63.26 | 2021-2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $42.16 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $29.11 | 2024 | Zoryve |
| Organon LLC | $25.21 | 2025 | |
| Revance Therapeutics, INC. | $17.98 | 2025 | Daxxify |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shellie Norman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.